pan-genotype HCV NS3/4A protease inhibitor proj. oral QD dosing, well-tolerated in rodent deuteration reduced CYP TDI J. Med. Chem., Nov. 23, 2020 Bristol-Myers Squibb, NJ + MA + CT + IN